RTP Mobile Logo
RTP On Demand: The Emerging and Potential Role of Chimeric Antigen Receptor T-Cell Therapy in the Management of Hematologic Cancers
Released February 2018

Proceedings from video interviews with Drs Frederick L Locke, David L Porter and Edward A Stadtmauer on the current and potential application of clinical research on chimeric antigen receptor T-cell therapy to the management of hematologic cancers.

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

    The recent success of checkpoint inhibitors in treating a number of types of cancer has sparked massive interest in the development of new immunotherapies. One promising approach is chimeric antigen receptor (CAR) T-cell therapy, in which a patient’s T lymphocytes are removed and reprogrammed ex vivo with genetically modified receptors that enable the cells to recognize a predetermined tumor antigen and mount an antitumor response. Recent data sets documenting the efficacy of CAR T-cell therapies across several hematologic cancers suggest that this treatment may significantly benefit patients with otherwise limited options. However, the unique nuances, toxicities and practical considerations surrounding this novel therapeutic method present a challenge to community-based clinicians. To bridge the gap between research and patient care, this special RTP On Demand program features one-on-one discussions with leading CAR T-cell therapy investigators. By providing information on the latest clinical developments in the context of expert perspectives, this CME activity allows medical oncologists, hematologists and hematology-oncology fellows to expand their knowledge, eliminate practice gaps and prepare themselves to deliver state-of-the-art care.


    • Develop an understanding of the biologic rationale for the development of CAR T-cell therapy as a strategy to eliminate targeted cancer cells, and appreciate the basics of the manufacturing and treatment process.
    • Appraise existing and emerging efficacy and safety data from early trials testing the use of CAR T-cell therapy in patients with relapsed/refractory B-cell cancers.
    • Recognize adverse events and other common side effects associated with CAR T-cell therapy, and implement supportive strategies to prevent and/or manage these complications.
    • Compare and contrast the mechanisms of action and toxicity of various CAR T-cell therapy platforms and other immunotherapies to help determine the potential utility of each in clinical practice.
    • Recall the scientific rationale for and new data supporting the ongoing investigation of novel applications of CAR T-cell therapy, and counsel appropriately selected patients about study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/RTPODCART117/Video/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Frederick L Locke, MD
    Vice Chair and Associate Member
    Research Director and Clinical Director for Immune Cell Therapy
    Department of Blood and Marrow Transplant and Cellular Immunotherapy
    Moffitt Cancer Center
    Tampa, Florida

    Advisory Committee: Kite Pharma Inc; Consulting Agreement: Cellular Biomedicine Group Inc.

    David L Porter, MD
    Jodi Fisher Horowitz Professor of Leukemia Care Excellence
    Director, Blood and Marrow Transplantation
    Abramson Cancer Center, University of Pennsylvania Health System
    Philadelphia, Pennsylvania

    Advisory Committee: Astellas Pharma Global Development Inc, Kite Pharma Inc; Employment/Salary: Genentech BioOncology; Patents: Novartis.

    Edward A Stadtmauer, MD
    Professor of Medicine
    Leader, Hematologic Malignancies Program
    Director, Bone Marrow and Stem Cell Transplant Program
    Division of Hematology-Oncology
    Abramson Cancer Center of the University of Pennsylvania
    Philadelphia, Pennsylvania

    Consulting Agreements: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Kite Pharma Inc and Novartis.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: February 2018
    Expiration date: February 2019

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Interview with Frederick L Locke, MD

Interview with David L Porter, MD

Interview with Edward A Stadtmauer, MD

Select Publications